Logo image of IDYA

IDEAYA BIOSCIENCES INC (IDYA) Stock Price, Quote, News and Overview

NASDAQ:IDYA - Nasdaq - US45166A1025 - Common Stock - Currency: USD

17.18  -0.27 (-1.55%)

IDYA Quote, Performance and Key Statistics

IDEAYA BIOSCIENCES INC

NASDAQ:IDYA (5/14/2025, 2:14:44 PM)

17.18

-0.27 (-1.55%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High44.42
52 Week Low13.45
Market Cap1.50B
Shares87.54M
Float86.63M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-04 2025-08-04
IPO05-23 2019-05-23


IDYA short term performance overview.The bars show the price performance of IDYA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

IDYA long term performance overview.The bars show the price performance of IDYA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40 -40

The current stock price of IDYA is 17.18 USD. In the past month the price increased by 1.99%. In the past year, price decreased by -56.91%.

IDEAYA BIOSCIENCES INC / IDYA Daily stock chart

IDYA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.43 316.65B
AMGN AMGEN INC 12.6 140.60B
GILD GILEAD SCIENCES INC 12.8 123.38B
VRTX VERTEX PHARMACEUTICALS INC N/A 107.87B
REGN REGENERON PHARMACEUTICALS 12.86 61.52B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 34.43B
ARGX ARGENX SE - ADR 90.86 32.56B
ONC BEIGENE LTD-ADR 5.51 23.93B
BNTX BIONTECH SE-ADR N/A 22.35B
NTRA NATERA INC N/A 20.59B
BIIB BIOGEN INC 7.61 17.64B
SMMT SUMMIT THERAPEUTICS INC N/A 16.98B

About IDYA

Company Profile

IDYA logo image IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The company is headquartered in South San Francisco, California and currently employs 131 full-time employees. The company went IPO on 2019-05-23. The firm is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).

Company Info

IDEAYA BIOSCIENCES INC

7000 Shoreline Ct, Suite 350

South San Francisco CALIFORNIA 94080 US

CEO: Yujiro Hata

Employees: 131

IDYA Company Website

IDYA Investor Relations

Phone: 16504436209

IDEAYA BIOSCIENCES INC / IDYA FAQ

What is the stock price of IDEAYA BIOSCIENCES INC today?

The current stock price of IDYA is 17.18 USD. The price decreased by -1.55% in the last trading session.


What is the ticker symbol for IDEAYA BIOSCIENCES INC stock?

The exchange symbol of IDEAYA BIOSCIENCES INC is IDYA and it is listed on the Nasdaq exchange.


On which exchange is IDYA stock listed?

IDYA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for IDEAYA BIOSCIENCES INC stock?

19 analysts have analysed IDYA and the average price target is 52.7 USD. This implies a price increase of 206.75% is expected in the next year compared to the current price of 17.18. Check the IDEAYA BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is IDEAYA BIOSCIENCES INC worth?

IDEAYA BIOSCIENCES INC (IDYA) has a market capitalization of 1.50B USD. This makes IDYA a Small Cap stock.


How many employees does IDEAYA BIOSCIENCES INC have?

IDEAYA BIOSCIENCES INC (IDYA) currently has 131 employees.


What are the support and resistance levels for IDEAYA BIOSCIENCES INC (IDYA) stock?

IDEAYA BIOSCIENCES INC (IDYA) has a support level at 17.42 and a resistance level at 18.35. Check the full technical report for a detailed analysis of IDYA support and resistance levels.


Is IDEAYA BIOSCIENCES INC (IDYA) expected to grow?

The Revenue of IDEAYA BIOSCIENCES INC (IDYA) is expected to grow by 228.54% in the next year. Check the estimates tab for more information on the IDYA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy IDEAYA BIOSCIENCES INC (IDYA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does IDEAYA BIOSCIENCES INC (IDYA) stock pay dividends?

IDYA does not pay a dividend.


When does IDEAYA BIOSCIENCES INC (IDYA) report earnings?

IDEAYA BIOSCIENCES INC (IDYA) will report earnings on 2025-08-04.


What is the Price/Earnings (PE) ratio of IDEAYA BIOSCIENCES INC (IDYA)?

IDEAYA BIOSCIENCES INC (IDYA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.3).


What is the Short Interest ratio of IDEAYA BIOSCIENCES INC (IDYA) stock?

The outstanding short interest for IDEAYA BIOSCIENCES INC (IDYA) is 12.56% of its float. Check the ownership tab for more information on the IDYA short interest.


IDYA Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to IDYA. When comparing the yearly performance of all stocks, IDYA is a bad performer in the overall market: 89.63% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

IDYA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to IDYA. While IDYA has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IDYA Financial Highlights

Over the last trailing twelve months IDYA reported a non-GAAP Earnings per Share(EPS) of -3.3. The EPS decreased by -67.51% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -24.42%
ROE -25.91%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-186.54%
Sales Q2Q%78.43%
EPS 1Y (TTM)-67.51%
Revenue 1Y (TTM)-70.06%

IDYA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 86% to IDYA. The Buy consensus is the average rating of analysts ratings from 19 analysts.

For the next year, analysts expect an EPS growth of 13.88% and a revenue growth 228.54% for IDYA


Ownership
Inst Owners109.03%
Ins Owners0.91%
Short Float %12.56%
Short Ratio7.86
Analysts
Analysts86.32
Price Target52.7 (206.75%)
EPS Next Y13.88%
Revenue Next Year228.54%